Previous close | 120.25 |
Open | 120.21 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 800 |
Day's range | 118.85 - 121.05 |
52-week range | 61.28 - 134.08 |
Volume | |
Avg. volume | 909,618 |
Market cap | 10.446B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.28 |
Earnings date | 27 Feb 2023 - 03 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 151.00 |
With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
SOMERSET, N.J. & CAMBRIDGE, Mass., January 05, 2023--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dy